Ra Pharmaceuticals Inc.
Developing oral peptide-like drugs using synthetic amino acids
Ra Pharmaceuticals Inc. is developing and establishing a new class of drugs called Cyclomimetics. The just-out-of-stealth-mode biotech says these drugs will be orally available peptide therapeutics combining the diversity and specificity of antibodies with some of the benefits of small molecules, including oral dosing and longer half-lives. Its first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.






